Login
Since the late 1990s, Merck has known that its measles, mumps and rubella (MMR) vaccine is significantly less effective than the company states on its product license and product insert.
Given that Merck’s own test results for the vaccine fell outside the specifications, or acceptance criteria established by the U.S. Food and Drug Administration (FDA) for drug applications, the production of this vaccine should have stopped, Merck should have suspended sales and the defective vaccine should have been withdrawn from the market with a product recall.
The Centers for Disease Control and Prevention (CDC) and other purchasers of the defective vaccine — and vaccine recipients — should have been informed.
None of this appears to have happened.
In April 2012, Stephen Krahling and Joan Wlochowski, virologists working for Merck in Pennsylvania — who became whistleblowers — filed two separate lawsuits against the pharmaceutical giant alleging it falsified research data, enabling it to develop a monopoly on the MMR vaccine and block any competition.
Evidence provided in expert witness reports from Dr. David A. Kessler, ex-commissioner of the FDA, Dr. Robert Malone and Merck’s own internal documents described the vaccine as “misbranded,” “out of compliance” and “non-marketable.”
According to witnesses and legal counsel for the whistleblowers, Merck scientists resorted to “falsifying data and destroying unfavorable data.”
An ineffective mumps vaccine is dangerous. Recipients of the vaccine are not protected or become susceptible to mumps again at an older age, leading to outbreaks in highly vaccinated populations.
For those contracting mumps after puberty, the disease is more dangerous. The risk of testicular inflammation and sterility, and ovarian and brain inflammation increases. The less effective vaccine has shifted mumps to young adults, who face increased safety risks.
Merck knows this.
In United States ex rel. Krahling v. Merck & Co., Krahling and Wlochowski have put compelling evidence of mumps vaccine fraud before the federal court in Philadelphia.
Their story is told by Yow Media in the award-winning movie, “Protocol 7,” set to play at local cinemas this evening, July 8, before the 3rd Circuit U.S. Court of Appeals hears oral arguments tomorrow.
Children’s Health Defense and the “Protocol 7” team will hold a vigil tomorrow, July 9, outside the court.
Tomorrow’s hearing before the 3rd Circuit challenges a recent ruling in favor of Merck, which held that Merck was not liable for fraud because the FDA did not require any changes and the CDC continued to purchase the vaccine.
For more information on the vigil, rally and hearing, click here.
To listen to the oral arguments, click here.
